Drug intelligence / Profile preview

SY001

Development stage: Phase 1
Lead developer: CellOrigin Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Subcutaneous

Overview

SY001 is a proprietary "off-the-shelf" iPSC-derived Chimeric Antigen Receptor Macrophage (CAR-iMAC) cell therapy developed by CellOrigin Biotech in collaboration with Qilu Pharmaceutical. It is designed for cancer immunotherapy, specifically targeting solid tumors. The partnership aims to accelerate its development and push it into clinical trials.

Targets

Mesothelin

Beyond the preview

Go deeper on SY001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY001.

Explore the full profile